; and (B) to hospitals, physicians, and other providers of services and suppliers with respect to fair price eligible individuals described in subparagraph (C) of such section administered such drug during, subject to subparagraph (2), the price applicability period; (2) the Secretary and the manufacturer shall, in accordance with a process and during a period specified by the Secretary pursuant to rulemaking, renegotiate (and, by not later than the last date of such period and in accordance with subsection (c), agree to) the maximum fair price for the drug if the Secretary determines that there is a material change in any of the factors described in section 1194(d) relating to the drug, including changes in the AIM price for the drug, in order to provide access to such maximum fair price (as so renegotiated)— (A) to fair price eligible individuals described in subparagraph (A) or (B) of section 1191(c)(1) furnished such drug during any year during the price applicability period (beginning after such renegotiation) with respect to such selected drug; and (B) to hospitals, physicians, and other providers of services and suppliers with respect to fair price eligible individuals described in subparagraph (C) of such section administered such drug during any year described in subparagraph (A); (3) the maximum fair price (including as renegotiated pursuant to paragraph (2)), with respect to such a selected drug, shall be provided to fair price eligible individuals described in subparagraph (A) or (B) of section 1191(c)(1) at the pharmacy or by the mail order service at the point-of-sale of such drug